Machine Learning

With backing from AstraZeneca and Pfizer, Beijing’s Syneron Bio is using its AI-driven platform to develop novel drugs for cancer and chronic illness.

In a fierce biotech talent war, Senti Bio's new equity grant for a key hire signals a strategic push for its gene therapy pipeline amid market volatility.

A historic U.S. executive order reclassifies cannabis, opening the door for pharmaceutical products. One Canadian firm is already years ahead of the curve.

With a massive capital raise and rapid microreactor progress, NANO Nuclear is positioning itself to power the AI boom and lead a new nuclear renaissance.

A new oral drug, cadisegliatin, enters a major clinical trial in the UAE, aiming to help Type 2 diabetes patients struggling with insulin therapy.

An executive order accelerates moving cannabis to Schedule III, promising massive tax breaks for businesses but leaving advocates wanting more federal reform.

A Minnesota startup has secured major funding to advance its bioelectronic device aimed at the brain's waste clearance system for treating CNS disorders.

The Channel Partners 2026 conference will address the rapid pace of AI and market shifts with its 'Channel Velocity' theme and a Robert Irvine keynote.

Interactive Brokers' redesigned GlobalTrader app blends AI-powered insights and a user-friendly interface to make global markets more accessible than ever.

European FinTech Multitude AG unveils its 2026 financial calendar, offering investors a clear roadmap amid strong growth and evolving market dynamics.

Bitwarden launches real-time vault alerts and password coaching, moving beyond simple warnings to actively guide users in securing their digital lives.

Facing market pressure, Mobileye plans a major CES 2026 reveal of its 'physical AI' and new chip architecture alongside key partner Volkswagen.

The AI defense firm's stock surged after announcing a share repurchase, a move reflecting deep internal confidence amid a booming defense-tech market.

RELEX Solutions' strategic acquisition of Ida aims to revolutionize fresh food management, promising less waste, higher sales, and a smarter supply chain.

Avantor appoints financial heavyweight Simon Dingemans to its board, a strategic move to accelerate its ambitious turnaround amid market pressures.

Newly public AI firm Fusemachines unveils an ambitious 2026 growth plan, but faces significant financial hurdles and deep investor skepticism.

Pharma giant GSK partners with biotech CAMP4, leveraging novel RNA-boosting tech to develop new therapies for neurodegenerative and kidney diseases.

With FDA approval for a pivotal study, Pulse Biosciences' novel nanosecond ablation technology aims to make atrial fibrillation treatment safer and more precise.

The automaker adopts advanced IP management software to protect its innovations in EVs and autonomous driving, signaling a critical industry-wide shift.

Molecular Partners readies for a pivotal presentation at the J.P. Morgan conference, showcasing its next-gen DARPin therapeutics for hard-to-treat cancers.